ViroGates A/S

ViroGates A/S EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of ViroGates A/S (VIRO.CO) as of Nov 22, 2026 is -8.05. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -6.74 — a change of 19.45% (lower).

EV/EBIT

-8.05

YoY

19.45%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of ViroGates A/S is 2025 -8.05 . EV/EBIT (Enterprise Value to EBIT) of ViroGates A/S was 2024 -6.74 . It decreases by 19.45% lower compared to the previous year.

The ViroGates A/S EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-6.26 DKK
Jan 1, 2019
-5.74 DKK
Jan 1, 2020
-5.74 DKK
Jan 1, 2021
-6.03 DKK
Jan 1, 2022
-10.44 DKK
Jan 1, 2023
-9.01 DKK
Jan 1, 2024
-6.74 DKK
Jan 1, 2025
-8.05 DKK
The ViroGates A/S EV/EBIT history
YEAREV/EBITYoY
-8.05+19.45%
-6.74-25.23%
-9.01-13.68%
-10.44+73.24%
-6.03+5.00%
-5.74-0.03%
-5.74-8.22%
-6.26-57.51%
-14.73-9.80%
-16.33-22.79%
-21.15—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ViroGates A/S Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides ViroGates A/S's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates ViroGates A/S's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots ViroGates A/S's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if ViroGates A/S grows earnings faster than its peers.

ViroGates A/S Stock analysis

What does ViroGates A/S do? ViroGates A/S develops and markets prognostic products for the healthcare sector, focusing on the suPARnostic product line that measures soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The suPARnostic Quantitative Point of Care Quick Triage test is designed for patient triage in acute care settings, while the Quantitative ELISA Assay targets clinical routine use. Healthcare providers, including hospitals and clinics, purchase these products to assess immune activation levels and monitor disease progression, particularly for conditions like HIV-1-infection, malaria, tuberculosis, and sepsis. The company generates revenue through the sale of these diagnostic tools to healthcare institutions for use in patient care and disease management. The suPARnostic product line serves as a marker for survival chances upon hospital admission and aids in early intervention by detecting elevated suPAR levels linked to increased inflammation and mortality risk. High suPAR levels are associated with infectious diseases such as Streptococcus pneumonia bacteraemia, pneumococcal pneumonia, and bacterial and viral CNS infections. Healthcare facilities utilize the quantitative tests to determine patient prognosis and guide treatment decisions, ensuring timely interventions that improve patient outcomes. ViroGates A/S monetizes its diagnostic solutions by supplying healthcare systems with tools that enhance clinical decision-making and patient monitoring capabilities. ViroGates A/S targets healthcare providers who require rapid and accurate diagnostic tools for acute care and routine clinical use. The company's products are specifically tailored for monitoring immune activation in patients with infectious diseases, offering both point-of-care testing and laboratory-based assays. By providing these specialized diagnostic solutions, ViroGates A/S supports healthcare institutions in managing patient care more effectively, leading to better health outcomes and reduced mortality rates. Revenue is derived from the direct sale of suPARnostic tests to hospitals, clinics, and other clinical facilities that integrate these tools into their diagnostic workflows. ViroGates A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViroGates A/S stock

EV/EBIT (Enterprise Value to EBIT) of ViroGates A/S is -8.05 in 2025.

EV/EBIT (Enterprise Value to EBIT) of ViroGates A/S changed from -6.74 to -8.05, representing a 19.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) ViroGates A/S since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s ViroGates A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — ViroGates A/S

All Key Metrics — ViroGates A/S